Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 5, 2015, Pages 580-582

  Kobayashi, Ryoji ^a   Sano, Hirozumi ^a   Suzuki, Daisuke ^a   Kishimoto, Kenji ^a   Yasuda, Kazue ^a   Honjo, Ryota ^b   Hirose, Mieko ^b   Fujita, Shoji ^b   Abe, Shuji ^b   Kobayashi, Kunihiko ^a  

^a SAPPORO HOKUYU HOSPITAL   (Japan)

^b Hakodate Goryokaku Hospital   (Japan)

Author keywords

hemophilia B; immune tolerance induction; rituximab

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 INHIBITOR; CD20 ANTIGEN; HYDROCORTISONE; PREDNISOLONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; COUGHING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEMARTHROSIS; HEMOPHILIA B; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFORMED CONSENT; JAPANESE (PEOPLE); LYMPHOCYTE COUNT; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PURPURA; TREATMENT DURATION; URTICARIA; GENETICS; INFANT; MALE;

ANTINEOPLASTIC AGENTS; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; RITUXIMAB;

EID: 84941564338     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000288     Document Type: Article

References (16)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-459
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598
3. Astermark J1, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008; 14 (Suppl 3): 36-42
4. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-315
5. Puetz J, Soucie JM, Kempton CL, Monahan PE, Hemophilia Treatment Center Network (HTCN) Investigators. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia 2014; 20: 25-31
6. Ewenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-1116
7. DiMichele DM1, Kroner BL, North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-57
8. Warrier I. Inhibitors in hemophilia. In: Lee CA, Berntorp E, Hoots WK. Textbook of hemophilia. Oxford and Malden MA: Blackwell Publishing; 2005. pp. 97-100
9. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-1031
10. DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159: 123-134
11. Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001; 114: 244-245
12. Saleh MN1, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27 (6 Suppl 12): 99-103
13. Chuansumrit A, Moonsup Y, Sirachainan N, Benjaponpitak S, Suebsangad A, Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysis 2008; 19: 208-211
14. Alexander S1, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008; 30: 93-95
15. Beutel K1, Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie 2009; 29: 155-157
16. Verghese P1, Darrow S, Kurth MH, Reed RC, Kim Y, Kearney S. Successful management of factor IX inhibitor-Associated nephrotic syndrome in a hemophilia B patient. Pediatr Nephrol 2013; 28: 823-826